Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INO-4500 in Healthy Volunteers
NCT03805984Phase 1Completed
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- May 2019
- Primary completion
- Oct 2020
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of INO-4500 in Lassa fever (4 arms), sponsored by Inovio Pharmaceuticals, Inc. Primary endpoints: Percentage of Participants with Adverse Events (AEs), Percentage of Participants with Injection Site Reactions and 1 more. Started May 2019; status: completed.
02
Drugs
INO-4500
03
Conditions
Lassa fever
Beyond the preview
Go deeper on NCT03805984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03805984.